Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep 9;9(9):CD012050.
doi: 10.1002/14651858.CD012050.pub2.

Statin withdrawal in people with dementia

Bernadette McGuinness  1 , Chris R Cardwell, Peter Passmore
Affiliations
Review

Statin withdrawal in people with dementia

Bernadette McGuinness et al. Cochrane Database Syst Rev. .

Abstract

Background: There are approximately 24 million people worldwide with dementia; this is likely to increase to 81 million by 2040. Dementia is a progressive condition, and usually leads to death eight to ten years after first symptoms. End-of-life care should emphasise treatments that optimise quality of life and physicians should minimise unnecessary or non-beneficial interventions. Statins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors; they have become the cornerstone of pharmacotherapy for the management of hypercholesterolaemia but their ability to provide benefit is unclear in the last weeks or months of life. Withdrawal of statins may improve quality of life in people with advanced dementia, as they will not be subjected to unnecessary polypharmacy or side effects. However, they may help to prevent further vascular events in people of advanced age who are at high risk of such events.

Objectives: To evaluate the effects of withdrawal or continuation of statins in people with dementia on: cognitive outcomes, adverse events, behavioural and functional outcomes, mortality, quality of life, vascular morbidity, and healthcare costs.

Search methods: We searched ALOIS (medicine.ox.ac.uk/alois/), the Cochrane Dementia and Cognitive Improvement Group Specialised Register on 11 February 2016. We also ran additional searches in MEDLINE, EMBASE, PsycINFO, CINAHL, Clinical.Trials.gov and the WHO Portal/ICTRP on 11 February 2016, to ensure that the searches were as comprehensive and as up-to-date as possible.

Selection criteria: We included all randomised, controlled clinical trials with either a placebo or 'no treatment' control group. We applied no language restrictions.

Data collection and analysis: Two review authors independently assessed whether potentially relevant studies met the inclusion criteria, using standard methodological procedures expected by Cochrane. We found no studies suitable for inclusion therefore analysed no data.

Main results: The search strategy identified 28 unique references, all of which were excluded.

Authors' conclusions: We found no evidence to enable us to make an informed decision about statin withdrawal in dementia. Randomised controlled studies need to be conducted to assess cognitive and other effects of statins in participants with dementia, especially when the disease is advanced.

PubMed Disclaimer

Conflict of interest statement

BMcG: none known

PP: none known

CC: none known

Update of

References

References to studies excluded from this review

Kutner 2015 {published data only}
    1. Kutner JS, Blachford PJ, Taylor Jr DH, Ritchie CS, Bull JH, Fairclough DL, et al. Safety and Benefit of Discontinuing Statin Therapy in the Setting of Advanced, Life‐Limiting Illness. A Randomized Clinical Trial. JAMA Intern Med 2015;175:691‐700. - PMC - PubMed
Padala 2010 {published data only}
    1. Padala KP, Padala PR, Potter JF. Statins: A case for drug withdrawal in patients with dementia. JAGS 2010;6:1214‐1216. - PubMed
Padala 2012 {published data only}
    1. Padala KP, Padala PR, McNeilly DP, Geske JA, Sullivan DH, Potter JF. The Effect of HMG‐CoA Reductase Inhibitors on Cognition in Patients with Alzheimer's Dementia: A Prospective Withdrawal and Rechallenge Pilot Study. The American Journal of Geriatric Pharmacotherapy 2012;10:296‐302. - PubMed
Tjia 2014 {published data only}
    1. Tjia J, Cutrona SL, Peterson D, Reed G, Andrade SE, Mitchell SL. Statin Discontinuation in Nursing Home Residents with Advanced Dementia. Journal of the American Geriatrics Society 2014;62:2095‐2101. - PMC - PubMed

Additional references

Alzheimer's Society 2014
    1. Dementia UK: Update Second edition, November 2014. Available from alzheimers.org.uk/dementiauk (accessed on 10/12/2015).
Amarenco 2009
    1. Amarenco P, Labreuche J. Lipid management in the prevention of stroke; review and updated meta‐analysis of statins for stroke prevention. Lancet Neurology 2009;8(5):453‐63. - PubMed
Baigent 2005
    1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol‐lowering treatment: prospective meta‐analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366(9493):1267‐78. - PubMed
Blass 2008
    1. Blass DM, Black BS, Philips H, Finucane T, Baker A, Loreck D, et al. Medication use in nursing home residents with advanced dementia. International Journal of Geriatric Psychiatry 2008;23(5):490‐6. - PubMed
Bowman 2014
    1. Bowman C, Meyer J. Formative care: defining the purpose and clinical practice of care for the frail. Journal of the Royal Society of Medicine 2014;107(3):95‐8. - PMC - PubMed
CTT Collaboration 2016
    1. Cholesterol Treatment Trialists' (CTT) Collaboration. Protocol for analyses of adverse event data from randomized controlled trials of statin therapy. American Heart Journal 2016;176:63‐9. - PMC - PubMed
Ferri 2005
    1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366(9503):2112‐7. - PMC - PubMed
Field 1997
    1. Field M, Cassell C. Institute of Medicine Report. Approaching Death: Improving Care at the End of Life. Washington, DC: National Academy Press, 1997. - PubMed
Gnjiidic 2015
    1. Gnjiidic D, Wilson N, March L, Cumming RG, Cameron ID, Hilmer SN. Statin utilisation patterns in older Australians living in residential care: 1‐year prevalence study. Internal Medicine Journal 2015;45:106‐9. - PubMed
Goldfine 2012
    1. Goldfine AB. Statins: is it really time to reassess benefits and risks?. New England Journal of Medicine 2012;366(19):1752‐5. - PubMed
GRADEproGDT 2015 [Computer program]
    1. McMaster University, developed by GRADE Working Group and Evidence Prime, Inc.. GRADEpro GDT: GRADEpro Guideline Development Tool. Available from: gradepro.org. Version (accessed on 22/12/2015). Hamilton, ON: McMaster University, developed by GRADE Working Group and Evidence Prime, Inc., 2015.
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Holmes 2008
    1. Holmes HM, Sachs GA, Shega JW, Hougham GW, Cox Hayley D, Dale W, et al. Integrating palliative medicine into the care of persons with advanced dementia: identifying appropriate medication use. Journal of the American Geriatrics Society 2008;56(7):1306‐11. - PubMed
Holmes 2009
    1. Holmes HM. Rational prescribing for patients with a reduced life expectancy. Clinical Pharmacology and Therapeutics 2009;85(1):103‐7. - PubMed
IQWIG 2015
    1. Institut für Qualität und Wirthschaftlichkeit im Gesundheitswesen. General Methods. Available from iqwig.de/download/IQWiG_General_Methods_Version_%204‐1.pdf 2015 (accessed 6 January 2016).
Kelley 2014
    1. Kelley BJ, Glasser S. Cognitive Effects of Statin Medications. CNS Drugs 2014;28:411‐419. - PubMed
Luchins 1993
    1. Luchins DJ, Hanrahan P. What is appropriate health care for end‐stage dementia?. Journal of the American Geriatrics Society 1993;41:25‐30. - PubMed
McGuinness 2014
    1. McGuinness B, Craig D, Bullock R, Malouf R, Passmore P. Statins for the treatment of dementia. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD007514.pub3] - DOI - PMC - PubMed
McGuinness 2016
    1. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database of Systematic Reviews 2016, Issue 1. [DOI: 10.1002/14651858.CD003160.pub3] - DOI - PMC - PubMed
McKeith 2005
    1. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. DLB Consortium. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. Neurology 2005;65(12):1863‐72. - PubMed
McKhann 2011
    1. McKhann GM, Knopman DS, Cherthow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers & Dementia 2011;7(3):263‐9. - PMC - PubMed
Mitchell 2009
    1. Mitchell SL, Teno JM, Kiely DK, Shaffer ML, Jones RN, Prigerson HG, et al. The clinical course of advanced dementia. New England Journal of Medicine 2009;361:1529‐38. - PMC - PubMed
Naci 2013
    1. Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study‐level network meta‐analysis of 246 955 participants from 135 randomized, controlled trials. Circulation. Cardiovascular Quality and Outcomes 2013;6(4):390‐9. - PubMed
Neary 1998
    1. Neary D, Snowden JS, Gustasfson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51(6):1546‐54. - PubMed
Onder 2013
    1. Onder G, Liperoti R, Foebel A, Fialova D, Topinkova E, Roest HG, et al. SHELTER Project. Polypharmacy and mortality among nursing home residents with advanced cognitive impairment: results from the SHELTER study. Journal of the American Medical Directors Association 2013;14(6):450.e7‐12. - PubMed
Ott 2015
    1. Ott BR, Daiello LA, Dahabreh IJ, Springate BA, Bixby K, Murali M, Trikalinos TA. Do statins impair cognition? A systematic review and meta‐analysis of randomized controlled trials. J Gen Intern Med 2015;30:348‐58. - PMC - PubMed
Parsons 2015
    1. Parsons C, McCann L, Passmore P, Hughes C. Development and application of medication appropriateness indicators for persons with advanced dementia: a feasibility study. Drugs & Aging 2015;32(1):67‐77. - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Richardson 2013
    1. Richardson K, Schoen M, French B, Umscheid CA, Mitchell MD, Arnold SE, Heidenreich PA, Rader DJ, deGoma EM. Statins and Cognitive Function. A Systematic Review. Annals of Internal Medicine 2013;159:688‐697. - PubMed
Román 1993
    1. Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS‐AIREN international workshop. Neurology 1993;43(2):250‐60. - PubMed
Rucker 2008
    1. Rücker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Medical Research Methodology 2008;8:79. - PMC - PubMed
Schünemann 2011
    1. Schünemann H, Hill S, Guyatt G, Akl EA, Ahmed F. The GRADE approach and Bradford Hill's criteria for causation. Journal of Epidemiology and Community Health 2011;65(5):392‐5. - PubMed
Spiegelhalter 2004
    1. Spiegelhalter DJ. Monitoring Clinical Performance: A commentary. The Journal of Thoracic and Cardiovascular Surgery 2004;128:820‐2. - PubMed
Sterne 2011
    1. Sterne JAC, Egger M, Mother D (editors). Chapter 10: Addressing reporting biases in: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Tjia 2010
    1. Tjia J, Rothman MR, Kiely DK, Shaffer ML, Holmes HM, Sachs GA, et al. Daily medication use in nursing home residents with advanced dementia. Journal of the American Geriatrics Society 2010;58(5):880‐8. - PMC - PubMed
Vollrath 2005
    1. Vollrath AM, Sinclair C, Hallenbeck J. Discontinuing cardiovascular medications at the end of life: lipid lowering medications. Journal of Palliative Medicine 2005;8(4):876‐81. - PubMed

LinkOut - more resources